Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

New Proteosome Inhibitor Carfilzomib Ready for Another Phase II Study

May 6, 2008

Analysis of:Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors | www.pipelinereview.com

The data from this phase Ib study will allow Proteolix to proceed with a phase II study of their novel proteasome inhibitor Carfilzomib in patients with advanced solid tumors. Phase II studies are already underway investigating its activity in myeloma, the tumor type shown to be sensitive to proteasome inhibition.

Rituxan and Lupus: Is there Hope for the Nephritis Study?

May 2, 2008

Analysis of:Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus | www.pipelinereview.com

This large study did not show any benefit for Rituxan in a general lupus population. But, patients with nephritis - a common kidney complication - were specifically excluded from this study and are specifically being studied with Rituxan in the LUNAR study, which will yield results in early 2009. It should be noted that Rituxan has recently shown promising activity treating other kidney ailments, including Hepatitis C associated cryoglobulinemic glomerulonephritis, idiopathic membranous nephropathy, and glomerulosclerosis.

Phase II Data are Intriguing for Boehringer Ingelheim's BIBF 1120 Pill in Pts with Advanced Lung Cancer

April 30, 2008

Analysis of:Data suggests promising overall survival and progression-free survival with Vargatef(TM) (BIBF 1120) | www.pipelinereview.com

This study is notable for several reasons: (1) it looked at 2 dose of BIBF 1120 and found essentially no difference in tumor control between the higher and lower dose regimens; (2) it included only patients who had previously received chemotherapy, and therefore, by definition, were less likely to have a good response (than in chemo-naïve patients); (3) healthier patients –described as “performance status 0-1”- demonstrated reasonable control of their tumors and reasonable survival rates. Put together, this is all encouraging, considering that they all had incurable, previously treated, advancing lung cancer and were only taking these new pills.

Oral PBI-1402 from ProMetic Life Sciences Inc. Might Have the Potential to Fill the Void Left by the EPO Stimulating Agents

April 25, 2008

Analysis of:Oral PBI-1402 Demonstrates Significant Activity in Chemeotherapy-Induced Anemia Phase II Clinical Trial | www.pipelinereview.com

While only a Phase II study, it suggest that Oral PBI-14 may be of significant help to cancer patients who suffer from anemia caused by their chemotherapy. http://www.pipelinereview.com/content/view/19152/109/ This is especially notable given the recent saftey concerns about and decline in use of Procrit and Aranesp - the only other drugs typically used to treat chemotherapy-induced anemia.

Previous Page : 1221 to 24 of 24

Subscribe to Updates

By RSS